(Reuters) - SkyePharma said the extra clinical work could delay the filing of Flutiform with the U.S. Food and Drug Administration until the second half of 2008 and could cost 3 million to 5 million pounds .
"We're talking to the FDA about how to address the particular point they've raised and it's going to depend on exactly what sort of clinical data they might need," Chief Operating Officer Ken Cunningham told Reuters.
Read more at Reuters.com Hot Stocks News
"We're talking to the FDA about how to address the particular point they've raised and it's going to depend on exactly what sort of clinical data they might need," Chief Operating Officer Ken Cunningham told Reuters.
Read more at Reuters.com Hot Stocks News
No comments:
Post a Comment